Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDG 16177

Next Previous
Drug Profile

IDG 16177

Alternative Names: IDG-16177; Xelaglifam

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ildong Pharmaceutical
  • Developer Evotec SE; Ildong Pharmaceutical
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Beta-arrestin stimulants; FFAR1 protein agonists; Gastrointestinal hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 26 Jun 2025 Preclinical development is ongoing in South Korea (Ildong Pharmaceuticals pipeline, June 2025)
  • 26 Jun 2025 Ildong Pharmaceuticals initiates enrolment in a phase I trial for Type 2 diabetes in unknown location (Ildong Pharmaceuticals pipeline, June 2025)
  • 19 Mar 2025 IDG 16177 is still in phase I trials for Type 2 diabetes mellitus in Germany (Yunovia Pipeline, March 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top